Stanford University
Showing 501-520 of 1,433 Results
-
Jeffrey Teuteberg
Professor of Medicine (Cardiovascular Medicine)
On Leave from 12/15/2025 To 12/14/2027BioHe is currently a Professor of Medicine at Stanford, but is no longer seeing patients as he is on leave and working with industry.
His research interests are in clinical outcomes in patients after transplant and mechanical support as well as novel approaches to immunosuppression. He has participated in many single-center and multi-institutional research studies and has published widely in the fields of transplant and mechanical support. He served as President of the International Society of Heart and Lung Transplantation in 2018. -
Winifred Teuteberg
Clinical Professor, Medicine - Primary Care and Population Health
BioDr. Teuteberg completed residency training in Internal Medicine at the University of Chicago and a Palliative Medicine Fellowship at Massachusetts General Hospital. She joined the faculty at Stanford in 2017 and currently sees patients as a part of the inpatient palliative care consult team at Stanford Healthcare.
She has been the clinical director or Stanford Medicine's implementation of the Ariadne Labs' Serious Illness Care Program since its inception in 2018. Her interests include communication skills training, leveraging predictive algorithms to identify patients who would most benefit from serious illness conversations, how to empower non-physician clinical team members to participate in this work, and best practice for EHR builds related to advance care planning. -
Haluk Tezcan, MD
Adjunct Clinical Associate Professor, Medicine - Oncology
BioClinical focus:
Breast Oncology
Molecular Diagnostics
Dr. Tezcan is a medical oncologist and hematologist with over three decades of diverse experience in cancer management and research.
He is leading the clinical development of Droplet Biosciences' novel liquid biopsy technology, a first-in-class lymphatic fluid molecular residual disease assessment, overseeing the scientific and clinical development of the technology. With over three decades of direct patient care and clinical trial experience as a principal investigator and director, both in academia and private practice, he has a firsthand understanding of the unmet clinical needs of physicians and patients, as well as broad experience in clinical trial design and implementation.
He is also co-principal at Athea Oncology, guiding practices and hospitals in developing clinical trial programs and high-value real-world data collection and diagnostic companies in clinical development. He is also a reviewer of JCO Precision Medicine.
Before joining Athea Oncology and Droplet Biosciences, he was the co-founder of LexentBio, which was successfully acquired by Roche/FMI. He also served as Director of Translational Medicine at Genomic Health and as Vice President, leading oncology development at Counsyl, where he integrated science with clinical product development. He established the CA.RE.foundation, a cancer research foundation dedicated to enabling the execution of clinical trials across community oncology sites throughout the Northwest US. He has independently built multiple software tools to help oncologists navigate the practical realities of their daily work.
